Compare CRCT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRCT | ANL |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 731.6M |
| IPO Year | 2021 | 2022 |
| Metric | CRCT | ANL |
|---|---|---|
| Price | $4.39 | $10.44 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 462.2K | 108.2K |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | ★ 22.20% | N/A |
| EPS Growth | ★ 20.69 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $708,780,000.00 | N/A |
| Revenue This Year | $0.08 | $36.02 |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | $43.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.74 | $0.88 |
| 52 Week High | $7.33 | $17.25 |
| Indicator | CRCT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 44.84 |
| Support Level | $4.16 | $9.46 |
| Resistance Level | $4.41 | $12.59 |
| Average True Range (ATR) | 0.13 | 1.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 57.01 | 42.74 |
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.